Business Context and Reporting Period
This Form 8-K is a current report filed by Intrexon Corporation (not Precigen, Inc.) on April 16, 2014. The filing addresses corporate governance changes regarding the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial statements or performance data.
Material Changes
- Director Resignation: Thomas D. Reed resigned from his position as a director effective April 16, 2014.
- Continued Employment: Dr. Reed will continue to serve as the Company's Chief Science Officer.
- Director Appointment: James S. Turley was appointed as a non-employee director effective April 16, 2014, to fill the vacancy left by Dr. Reed.
- Committee Assignments: Mr. Turley has not been named to any Board committees at this time.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, management commentary on financial performance, or discussion of risks and contingencies. Mr. Turley is eligible to participate in the Company's compensation arrangements for non-employee directors as described in the annual proxy statement.
Investor Verification Checklist
- Verify the correct registrant name is Intrexon Corporation, not Precigen, Inc.
- Confirm the effective date of the Board changes (April 16, 2014).
- Review the Company's annual proxy statement for details on non-employee director compensation.
- Check subsequent filings for any committee assignments for the new director, James S. Turley.